Beijing Genestart Biotechnology Co., Ltd. has recently declared the successful closure of a new financing round, raising over 100 million yuan. Renhe Capital took the lead in this financing endeavor, and the proceeds will be mainly allocated to propel the clinical trials of iNKT cell therapies forward, as well as to fuel the research and development (R&D) of new product pipelines. Established in 2015, Genestart stands as the world's pioneer in the R&D of therapeutic products centered around iNKT cells, equipped with a fully integrated technological platform system. iNKT cells, which exhibit traits of both T cells and NK cells, hold immense promise in the realm of tumor immunotherapy. Utilizing its proprietary technology, Genestart has adeptly accomplished the high-quality, large-scale production of iNKT cells, marking a series of breakthroughs. These achievements not only spur the advancement of related industries but also offer patients innovative treatment alternatives.